Silence Therapeutics plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Silence Therapeutics plc
After the recent spike in COVID-19, China has allowed the public to buy rapid antigen home-use tests. Prices offered in a recent government tender were cut by over 50% as local manufacturers rushed meet the demand opportunity.
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Atugen AG
- Intradigm Corporation
- SR Pharma plc